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Abstract
Background: In 2003, the National Institute of Mental Health funded the Child and Adolescent Psychiatry
Trials Network (CAPTN) under the Advanced Center for Services and Intervention Research (ACSIR)
mechanism. At the time, CAPTN was believed to be both a highly innovative undertaking and a highly
speculative one. One reviewer even suggested that CAPTN was "unlikely to succeed, but would be a
valuable learning experience for the field."
Objective: To describe valuable lessons learned in building a clinical research network in pediatric
psychiatry, including innovations intended to decrease barriers to research participation.
Methods:  The CAPTN Team has completed construction of the CAPTN network infrastructure,
conducted a large, multi-center psychometric study of a novel adverse event reporting tool, and initiated
a large antidepressant safety registry and linked pharmacogenomic study focused on severe adverse
events. Specific challenges overcome included establishing structures for network organization and
governance; recruiting over 150 active CAPTN participants and 15 child psychiatry training programs;
developing and implementing procedures for site contracts, regulatory compliance, indemnification and
malpractice coverage, human subjects protection training and IRB approval; and constructing an innovative
electronic casa report form (eCRF) running on a web-based electronic data capture system; and, finally,
establishing procedures for audit trail oversight requirements put forward by, among others, the Food and
Drug Administration (FDA).
Conclusion:  Given stable funding for network construction and maintenance, our experience
demonstrates that judicious use of web-based technologies for profiling investigators, investigator training,
and capturing clinical trials data, when coupled to innovative approaches to network governance, data
management and site management, can reduce the costs and burden and improve the feasibility of
incorporating clinical research into routine clinical practice. Having successfully achieved its initial aim of
constructing a network infrastructure, CAPTN is now a capable platform for large safety registries,
pharmacogenetic studies, and randomized practical clinical trials in pediatric psychiatry.
Published: 25 March 2009
Child and Adolescent Psychiatry and Mental Health 2009, 3:12 doi:10.1186/1753-2000-3-12
Received: 25 September 2008
Accepted: 25 March 2009
This article is available from: http://www.capmh.com/content/3/1/12
© 2009 Shapiro et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Child and Adolescent Psychiatry and Mental Health 2009, 3:12 http://www.capmh.com/content/3/1/12
Page 2 of 13
(page number not for citation purposes)
Review
Clinical research networks are envisioned in the NIH
roadmap as a means to reduce the costs associated with
launching multi-center studies while increasing patient
and physician participation in clinical research, which
together should accelerate the pace of medical discovery
[1,2]. By clinical trials network we mean a clinical trial
coordinating center and a group of clinical trials sites that
together are capable of conducting multiple and/or
sequential clinical trials and safety registries that where
appropriate smooth the progress of biomarker discovery.
The Child and Adolescent Psychiatry Trials Network
(CAPTN) is among the largest and most sophisticated of
seventy-six clinical research networks targeting children
and adolescents [3]. The stated mission of CAPTN is to
improve the care of children and adolescents with mental
illness through innovative clinical research. To accom-
plish this mission and expand the evidence base in pedi-
atric psychopharmacology, CAPTN seeks to conduct
practical clinical trials (PCTs) that evaluate the benefits
and harms of widely-used but under-studied medications
when conducting such a study that would then serve an
important public health need.
In late 2003, we initiated a partnership between the Duke
Clinical Research Institute and the American Academy of
Child and Adolescent Psychiatry to develop CAPTN as a
"proof of concept" PCT network, the first of its kind in
psychiatry, adult or pediatric. Funding for CAPTN came
from the National Institute of Mental Health (NIMH)
through the Advanced Center for Services and Interven-
tion Research (P30) grant mechanism. Since then, CAPTN
has conducted one multi-center research study focused on
developing and validating a novel drug adverse events
detection tool, the Pediatric Adverse Event Rating Scale
(PAERS), and is in the process of conducting two linked
multi-national studies focused on (1) antidepressant
safety and the pharmacogenetics of antidepressant
response and (2) a randomized controlled trial of newer
versus older treatments for ADHD. The Antidepressant
Safety in Kids (ASK: NCT00395213) study is a prospective
longitudinal cohort "safety registry" study of predictors of
benefits and adverse events in 500 youth with a depres-
sive, anxiety, obsessive-compulsive or eating disorder
exposed to an SSRI or SNRI. Running as a substudy within
ASK, the Pharmacogenomics of Antidepressant Response
in Children and (PARCA: NCT00516932) study is a
nested genetic case-control association study evaluating
the contribution of selected candidate genes as risk factors
for a suicidal event behavioral activation or their associa-
tion. The Newer Versus Older Treatments for ADHD
(NOTA) study is an equipoise-stratified randomized con-
trolled trials comparing for treatments for ADHD: Methyl-
phenidate Transdermal System (Daytrana),
Lisdexamfetamine dimesylate (Vyvanse), OROS MPH
(Concerta), and Mixed Amphetamine Salts Extended
Release (Adderall XR).
At the point we began to seek NIMH funding, CAPTN was
believed to be both a highly innovative undertaking and a
highly speculative one. One reviewer even suggested that
CAPTN was "unlikely to succeed, but would be a valuable
learning experience for the field." In actuality, many les-
sons have been learned in the process of moving CAPTN
from concept to functioning PCT network that are of gen-
eral importance for practical clinical trialists and, in par-
ticular, for those seeking to create multi-center clinical
trials networks in pediatric and adult psychiatry. In previ-
ous reports we documented the need for PCTs in pediatric
psychopharmacology [4], described common obstacles to
conducting PCTs in psychiatry and proposed a set of solu-
tions [5], and presented a theoretical rationale for CAPTN
[3]. In this article, we specifically focus on infrastructure
development issues (the "hardware") that enables practi-
cal clinical trials (the "software") to run on CAPTN.
Background
In the October 3rd, 2003 issue of Science, the Director of
the National Institutes of Health (NIH), Dr. Elias
Zerhouni, described a roadmap for clinical research that
included three guiding principles believed to be funda-
mentally important for improving patient care outcomes
[1]: (1) develop partnerships among and better integra-
tion between organized patient communities, commu-
nity-based physicians, academic researchers, and the NIH,
(2) develop new ways to organize how clinical research
information is recorded and make greater use of modern
information technologies, and (3) devise new standards
for clinical research protocols.
Consistent with the Roadmap initiative, CAPTN is prem-
ised on the belief that an expansion of partnerships
among stakeholders – academia, pharma, the FDA, the
NIH and patient advocacy groups – will facilitate a public-
health oriented research agenda that is based on the med-
ical needs of patients and the informational needs of phy-
sicians and healthcare policy-makers making patient care
decisions [4].
Almost two decades ago, Sir Richard Peto, who coined the
term large, simple trial [6], proposed that treatment out-
come studies should have sufficient power to identify
modest clinically relevant effects, employ randomization
to protect against bias, and be simple enough to make par-
ticipation by patients and providers reasonable [7]. More
recently, Sean Tunis at the Center for Medical Services
(CMS) described the defining features of an effectiveness
trial as comparing clinically important interventions, a
diverse population of study participants representative of
clinical practice, a heterogeneous practice setting also rep-Child and Adolescent Psychiatry and Mental Health 2009, 3:12 http://www.capmh.com/content/3/1/12
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resentative of clinical practice, and a broad range of clini-
cally relevant health outcomes [8]. Building on Peto and
Tunis, we recently made the case for practical clinical trials
in psychiatry [5]. Consistent with the proposed PCT
framework, we formatted the network infrastructure so
that PCTs conducted on CAPTN would be characterized
by eight defining principles: (1) Questions must be sim-
ple, clinically relevant, and of substantial public health
importance; (2) PCTs are performed in clinical practice
settings; (3) study power is sufficient to identify small-to-
moderate effects; (4) treatments should be in clinical
equipoise; (5) treatment conditions should be randomly
assigned to protect against bias; (6) outcome measures
should be simple and clinically relevant; (7) treatments
and assessments should enact a best practice standard of
care; and (8), subject and investigator burden associated
with research should be minimized.
While these characteristics are widely applicable to PCTs
in general and, hence, are held in common by practical
clinical trialists independent of discipline [9,10], some of
the challenges that we faced in developing a PCT network
in pediatric psychiatry are specific to the field of pediatric
psychiatry itself. Both field-specific and more general
challenges provide instructive lessons for those seeking to
instantiate the PCT model in that they provide insight into
the factors that may inhibit or, conversely, facilitate net-
work creation.
Network organization and governance
Figure 1 outlines the CAPTN organizational structure,
including trial leadership, governance and coordination,
sponsors, advisory boards, partners, network sites, infra-
structure capabilities and projects.
Executive Committee
Adopting a proper network governance structure is criti-
cally important to the overall success of a multicenter clin-
ical trials network. Thus, the first step in creating a
collaborative research network, such as CAPTN, was to
devise a system for governing the network and enlisting a
core group of researchers to take on the managerial chal-
lenges. In this regard, CAPTN has benefited from its prox-
imity to many NIH- and foundation-funded research
network initiatives based at the Duke Clinical Research
Institute. As the oldest and largest academic research
organization (ARO) in existence, the DCRI http://
www.dcri.duke.edu employs state-of-the-art operational
capabilities, including data and site management, biosta-
tistics, and safety surveillance, to facilitate the develop-
ment, conduct and dissemination of results for NIH and
industry funded randomized controlled trials or safety
registries. Moreover, the DCRI is a pillar in the Duke
Translational Medicine Institute (DTMI: http://
www.dtmi.duke.edu), which is designed to address T1, T2
and T3 translation blocks identified on the NIH Road-
map.
Thus, we were able to draw upon significant expertise
when considering the organizational design of the CAPTN
coordinating center. In every organization, leadership
must take on the questions of "Who sets the questions or
agenda?", "Who has a seat at the table?" and "Where does
the final authority lie?" Many network exercises fail
because the network leadership reflects either implicit or
explicit strategic agreements among powerful site-based
principal investigators who as often as not have little or no
track record of working together that everyone will "have
a piece of the pie." Put differently, many clinical trials net-
works are (usually covertly) structured to serve the scien-
tific and financial interests of the investigators rather than
to meet the mission statement of the network itself. A
clear line of authority is necessary to help insure that net-
work members remain stakeholders for the primary mis-
sion of the network. Absence of a clear governance
structure devoted to the success of the network as a whole,
or a failure in process, including means for reconciling
disputes, often leads to the formation of subgroups based
Child and Adolescent Psychiatry Trials Network (CAPTN) Figure 1
Child and Adolescent Psychiatry Trials Network 
(CAPTN). Proposed organizational structure for CAPTN 
during the second five years ofNIMH funding. ISAB = internal 
scientific advisory board; ESAB = externalscientific advisory 
board; DSMB = data safety and monitoring board; IRB = insti-
tutional review board; AACAP = American Academy of 
Child and Adolescent Psychiatry; SODBP = Society for 
Developmental and Behavioral Pediatrics. Pilot projects are 
small feasibility studies design to gatherpreliminary data to 
support developmental studies, which are R34 likeprelimi-
nary studies intended to construct trial infrastructure and 
materialsin preparation for R01-like PCTs, safety registries 
or biomarker/biosignatureprojects.Child and Adolescent Psychiatry and Mental Health 2009, 3:12 http://www.capmh.com/content/3/1/12
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on self-interests, studies burdened with irrelevant and
costly instruments and procedures, sluggish progress on
study design and implementation, and poor site and
patient enrollment. In developing CAPTN, we explicitly
wanted the network to serve the interests of mentally ill
children and their doctors. We also wanted clear lines of
decision making in which all the major stakeholders in
pediatric psychiatry were represented, and we wanted to
maximize the public health value of every dollar spent on
CAPTN.
From the outset, governance was entrusted to a core
group, the CAPTN Executive Committee that is composed
of Duke University faculty, the Project Leader from the
DCRI, and representatives from the site management,
data management and statistics functional groups. With
weekly meetings, this group provides a forum for both
strategic decision-making and for overseeing the day-to-
day operations of the coordinating center ensuring that
regular progress is made on all activities essential to the
functioning of the network.
Advisory Boards
Advising the Executive Committee is a larger group of
stakeholder experts: the CAPTN Steering Committee.
Prior to the funding of CAPTN, we solicited commitments
from key stakeholders in the field of child and adolescent
psychiatry. Among these were senior leadership from the
AACAP, including representation from both the AACAP
Council and the AACAP Workgroup on Research, NIMH
Program staff, and a representative from the National Alli-
ance for the Mentally Ill (NAMI). In addition, experts
from academia were recruited to offer diverse viewpoints
including child psychiatrists, psychopharmacologists, a
medical practice researcher, and a pharmacoepidemiolo-
gist, all of whom were based outside of Duke University.
After funding for CAPTN was received, a representative
from the NIMH program office, Dr. Benedetto Vitiello,
who consulted to us during the ACSIR application proc-
ess, was added as an ex officio member.
The core members of the Steering Committee were sup-
plemented with rotating at-large appointments from par-
ticipating network members. More than a dozen
physicians responded to our initial request for applicants
to join the CAPTN Steering Committee. Selecting appli-
cants for the 2 1/2 year appointments proved to be more
challenging than anticipated. Applicants were all highly
qualified and diverse in the education, research experi-
ence, practice setting, and geographic location, among
other factors. Ultimately, the committee selected three
applicants who were primarily clinic-based practitioners
but each of whom had some prior research exposure. The
purpose of this decision was to provide a reality check for
the Steering Committee in terms of the additional bur-
dens that we, as researchers, were asking of busy clini-
cians. While the stated purpose of the Steering Committee
was to serve an active if consulting role in managing the
network and collaborating on CAPTN trials, the focus on
developing and refining the CAPTN infrastructure (a proc-
ess largely internal to the DCRI) and the fact that the SC
members were for the most part too busy to take other
than a distant advisory role in CAPTN meant that the SC
became in practice more like a traditional external scien-
tific advisory board. Accordingly, going forward, the SC
model will be supplanted with a smaller advisory External
Scientific Advisory Board.
Our third group of advisors was an internal Scientific
Advisory Board. This group was composed of advisors, all
from Duke University, in fields ranging from ethics, law,
regulation, statistics, medicine, and clinical research. The
purpose of this body was to help the CAPTN Executive
Committee overcome obstacles or barriers to research that
emerged from either internal or external factors. Among
the areas that this group advised on were related to struc-
turing contracts, funding for research participation, Feder-
alwide assurances, and ethical oversight for those
unaffiliated with an institution with an IRB, bureaucratic
inefficiencies within the Duke system, and fitting the mis-
sion of the network to the changing regulatory environ-
ment. In particular, many of the challenges we faced as a
psychiatric network were related to difficulties transport-
ing the mega-trials network model from areas of medicine
that take place within facilities with a history of medical
research, such as oncology and cardiology, to an area that
takes place largely in small, out-patient practice settings.
Dispute Resolution
In the rapidly changing landscape of medicine, particu-
larly in the area of drug safety research, the governance
structure must accommodate a need for swift dispute res-
olution, should such disputes arise. Thus, the Principal
Investigator was responsible for bringing consensus to the
Executive Committee. In cases where consensus could not
be reached, the Executive Committee consulted with the
Steering Committee. The Scientific Advisory Board was
available for consultation about specific challenges or
general guidance about factors outside of pediatric psychi-
atry that nonetheless impacted the network or its research
aims. To ensure efficient decision-making, the PI retained
final authority over decisions, however with escalation
and consultation, the Executive Committee was able to
reach consensus over major decisions, the most challeng-
ing of which was related to the collection and reporting of
Serious Adverse Events (SAEs). This is described below in
the section on AE reporting.Child and Adolescent Psychiatry and Mental Health 2009, 3:12 http://www.capmh.com/content/3/1/12
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CAPTN Investigators
Recruitment
Finding clinicians willing and able to participate in clini-
cal research has been a challenge in many areas of medi-
cine, including child and adolescent psychiatry. Of the
20,000 cardiologists in the United States, fewer than 1000
(.5%) participate in research. Currently, there are approx-
imately 7,000 child and adolescent psychiatrists in the
United States and, when we began CAPTN in 2003, only
a handful were primarily engaged in clinical research.
Thus, the support of the AACAP was critical for our initial
and ongoing investigator recruitment strategies. Through
a series of surveys, conducted initially at the AACAP
annual meetings on paper, and later through the CAPTN
web site, we detected a significant level of interest in clin-
ical research among AACAP members: Approximately 300
child and adolescent psychiatrists responded to these
early surveys indicating a interest in clinical research
within the field, but significant uncertainty as to how one
might begin performing clinical research and what addi-
tional demands such research would place on clinicians.
These surveys were the basis for our initial claim that it
would be feasible to recruit and train approximately 200
investigators to join CAPTN and conduct a series of clini-
cal trials. This figure (.3%) is well within the range of
research participation by members of the American Col-
lege of Cardiology, but far smaller than the near 100%
participation rate in the Children's Oncology Group,
which sees 95% of youth with cancer.
Once CAPTN was funded, we began by contacting the
respondents to our initial feasibility surveys. In addition,
we reached out through the AACAP to their membership
through their web site, email, and at the AACAP Annual
Meeting. We asked those interested to complete an inter-
est questionnaire with their contact information and qual-
ifications. During this initial phase of investigator
recruitment, we succeeded in identifying 235 child and
adolescent psychiatrists who indicated an interest in
CAPTN. Including members associated with resident
training programs in child and adolescent psychiatry,
approximately 150 of these completed the progression
from interest to completing a master contract and the
CAPTN requirements for human subjects protection. This
process took almost three years for reasons outlined
below. We also quickly realized that in a group this large,
a handful of people in any given month would need to
suspend their participation due to circumstances. Ulti-
mately, in a large research network, a certain amount of
"churn" is inevitable. In CAPTN, this turns out to be about
10% of the network membership per year either tempo-
rarily suspend their participation or permanently do so.
Common reasons for this were moves, retirement, and
personal reasons, such as divorce or family emergencies.
This is an important consideration for those constructing
such networks since a steady-state network of 200 investi-
gators must recruit and train about twenty new members
per year to sustain itself.
Training Programs
Other than at a small number of research-oriented aca-
demic medical centers, clinical research has not histori-
cally been part of a child and adolescent psychiatrists'
residency or fellowship training. Indeed, a survey of clini-
cal trials publications in pediatric psychopharmacology
reveals a core group of fewer than 25 principal investiga-
tors located mostly at prominent academic centers that are
responsible for the majority of recent pediatric psychop-
harmacology literature. Fortunately, what we noticed
from our initial recruitment efforts was that the majority
of our members were coming from outside of these major
academic medical centers. While this was consistent with
our goal of recruiting primarily clinicians, rather than
researchers, our long-term network growth strategy was
based on reaching out to residency and fellowship train-
ing programs. Our intention was to interest trainees in
research during their fellowship with the hope that they
would choose to continue conducting CAPTN clinical tri-
als after completing their training.
Dr. Allan Chrisman, Child and Adolescent Psychiatry
Training Director at Duke, and a member of CAPTN's
Executive Committee, developed a training program spe-
cific initiative to identify and recruit CAPTN members at
facilities with ACGME certified residency training pro-
gram. Through his efforts at AADPRT and the AACAP
Workgroup on Training, we signed up fifteen child and
adolescent psychiatry training programs, each of which
agreed to engage their trainees in CAPTN research proto-
cols. This outreach coincided with an increased emphasis
on research in the accreditation guidelines for psychiatry
training programs, and the training we offered was a
mechanism for many programs to achieve this target. For
research networks, partnership with training programs is
a critical strategy for ensuring continued growth in net-
work membership, but more importantly, trainees staff-
ing busy clinics serve as a force multiplier, substantially
increasing the capacity of the research network to enroll
patients.
International Members
Interestingly, while CAPTN was conceived of as a domes-
tic (i.e., United States only) undertaking, our early surveys
showed a strong interest among Canadian members of the
AACAP. Following discussions with the program office
and an application for Fogarty Center clearance, we pro-
ceeded with enrolling Canadian child and adolescent psy-
chiatrists and training programs. Although the drugs in
use differ somewhat country-to-country, a multi-national
expansion of clinical research networks will be essentialChild and Adolescent Psychiatry and Mental Health 2009, 3:12 http://www.capmh.com/content/3/1/12
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for achieving the very large sample sizes that have become
common in PCTs in, for example, cardiology. Within
CAPTN, we are actively working to develop systems for a
broader expansion into additional countries over the next
few years.
Regulatory Compliance
One of the main justifications given for clinical research
networks is the perceived savings associated with recruit-
ing clinical trial sites once rather than ad hoc each time a
new study is conceived or funded. To realize these cost
savings for a post-marking drug research network, such as
CAPTN, we set out to define a minimum set of require-
ments necessary for investigator participation that would
meet applicable regulatory requirements. This activity led
to conversations with a wide variety of stakeholders
within the Duke community, and ultimately, to a number
of investigator and site requirements. The burdens associ-
ated with these requirements proved to be a significant
barrier to investigator recruitment and participation.
Site Contracts
Among these requirements was an executed site contract.
Clinical trial site contracting has traditionally been per-
ceived of as both slow and cumbersome, particularly
when the contracting offices of major universities are
involved. Because of the time and difficulty involved with
these negotiations, many in the pharmaceutical and con-
tract research industries eschew academic sites that are not
considered to be opinion leaders within the field. There-
fore, we had hoped to simplify the process and, in some
respects, succeeded, but discovered many barriers to
research that were nearly insurmountable within the
modern university architecture.
To participate in CAPTN, all site principal investigators
must sign a Master Services Agreement. Ultimately, this
agreement was pared to seven pages in length but was
complicated by several possible combinations of attach-
ments specific to type of facility at which the investigator
worked. Under the MSA-model, future studies are all cov-
ered under two-page, study-specific contract addenda.
Although we hoped for shorter, simpler contracts, we
found that most investigators found the proposed lan-
guage acceptable without modification. However, more
lengthy negotiations ensued with other universities. For
example, Arizona state law now makes all records of state
universities part of the public record. For the participation
of state universities in Arizona this necessitated specific
language to protect the confidentiality of study records
and meant that the study coordinating center had to mark
all study-materials sent to the site as "confidential." How-
ever, the single largest contractual barrier we encountered
was the issue of indemnification and medical malpractice
liability insurance.
Indemnification
While industry sponsors of clinical research regularly
indemnify clinical researchers for activities related to the
performance of a clinical study, the Federal government
provides no such indemnification for clinical trials. For
Duke University's Risk Management office, a large, com-
munity-based clinical research network, such as CAPTN,
presented a significant potential change in litigation expo-
sure. Ultimately, it was decided that for us to proceed, we
had to document the presence of $3 M per incident and
$5 M annual aggregate professional liability insurance for
all CAPTN investigators. This was coupled with a review
by Risk Management related to the solvency of the insurer
and history of jury awards within each investigator's
locale. While the time involved in collecting and review-
ing these documents slowed the contracting process, it
turned out that their standards were significantly higher
than what is standard within child and adolescent psychi-
atry, where we found that about 90% of practitioners had
coverage of $1 M per incident and $3 M annual aggregate.
We were frequently able to obtain waivers on a case-by-
case basis for those with less than the required $3 M/$5 M
coverage allowing them to participate in those CAPTN
studies that were considered non-interventional or mini-
mal risk under 45 CFR 46 Subpart D. This degree of cau-
tion is likely to be general for large institutions and those
that self-insure since widely distributed geographic expo-
sure and lesser oversight of extramural researchers in a
multi-center setting may affect risk exposure and hence,
the costs of re-insurance. Ultimately, we were able to pro-
ceed with minimal risk research, but this issue reemerged
when we began looking to expand CAPTN beyond the
United States. These experiences are described below in
the section on international research.
Oversight: Institutional Review Board
Regardless of the funding source, clinical research must be
subject to the oversight of a duly constituted IRB or equiv-
alent body. In the case of CAPTN, the Duke University
Health System IRB agreed to serve as the IRB of record for
those sites without access to a local IRB. The mechanism
to allow this is the Unaffiliated Investigator Agreement
(UIA), which was provided to those in solo practice who
enrolled in CAPTN. In this arrangement, individual clini-
cians agree to operate under the purview of the DUHS IRB
with the UIA provided as an attachment to the MSA
described above. However, it was determined that Duke
would not add external institutions to its Multiple Project
Assurance (MPA); later replaced by a Federalwide Assur-
ance or (FWA). Thus, group practices and institutions
without a local IRB would be required to possess a Feder-
alwide Assurance. The FWA is a binding agreement to con-
duct clinical research in compliance with the ethical
principles outlined in the Belmont Report of 1977 (for
those facilities located in the United States) or equivalentChild and Adolescent Psychiatry and Mental Health 2009, 3:12 http://www.capmh.com/content/3/1/12
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(e.g., the Tri-Council Policy Statement in Canada). Thus,
for CAPTN, we helped 21 institutions to complete and file
an FWA with the Office of Human Research Protection
(OHRP). The FWA includes specific terms which the insti-
tution must agree to abide by in order to receive the assur-
ance. In addition to identification of a Human Protection
Administrator, the facility must adopt written policies and
procedures to ensure compliance with ethical and regula-
tory requirements. While CAPTN has helped facilities
develop these procedures, some potential CAPTN partici-
pants balked when confronted with the time commitment
necessary to complete the training and adopt the formal
procedures required.
Regulatory Documentation
In addition to the contractual demands of research,
another significant burden is the collection and mainte-
nance of essential regulatory documents. For studies con-
ducted under an IND pursuant to 21 CFR 312, this
documentation includes a form FDA 1572, investigator
resumes or curricula vitae, and medical licensure for every
site participating in the research. Finally, in psychiatry,
and in particular, in child and adolescent psychiatry, use
of medications scheduled under the Controlled Sub-
stances Act is commonplace (for treatment of Attention
Deficit Hyperactivity Disorder). Since it was highly prob-
able that we would conduct studies in this area, we opted
to require network members to have prescribing authority
under the CSA. This is commonly documented by the
form DEA 223.
To date, CAPTN studies have not required an IND,
although this might be expected in some cases, since
many, if not most, medications used in this area are
approved for use in adults, but not in children. Therefore,
we felt that the collection and maintenance of regulatory
documents should be sufficient to meet the requirements
of an IND study, following the stipulation of 21 CFR
312.53 and ICH 4.1.1 which require that sponsors of
research document that clinical investigators are qualified
to conduct studies of the investigational product. For
CAPTN, this has been defined to mean those physicians
who are licensed in good standing to practice medicine
and have completed specialty training in psychiatry and
child and adolescent psychiatry. We documented this
with information from the American Board of Medical
Specialties (ABMS) and AACAP, whose databases allow us
to verify that our investigators have completed the
required residency training and board certification. How-
ever, as an NIH-funded enterprise, CAPTN is also subject
to the requirements of 45 CFR 46.
For federally-funded studies, an NIH format BioSketch
takes the place of curriculum vitae. In addition, human
subjects' protection training and a Federalwide Assurance
(for studies that are more than Minimal Risk under 45
CFR 46 Subpart D) are also required. For community sites,
the human subjects' protection in research training
requirement is typically met with the on-line module enti-
tled "Human Participant Protections Education for
Research Teams." This module is available from the
National Cancer Institute through their web site at http://
cme.cancer.gov/clinicaltrials/learning/humanparticipant-
protections.asp. It is important to note that many Institu-
tional Review Boards (IRBs) require their own training
modules which we allowed as substitutes for this training
by those operating under a local IRB, if the local IRB was
registered with OHRP and the institution had an active
FWA. This required training takes approximately an hour
to complete on-line and provides a certificate document-
ing completion of the training. For a small fee Continuing
Medical Education (CME) credit is available.
Clinical researchers may be audited by any of several
agencies that are empowered to restrict their ability to par-
ticipate in clinical research. Among these are the OHRP,
NIH Office of Civil Rights, and the FDA's BioResearch
Monitoring Program. We require that all members be
unrestricted by any of these regulatory agencies with
respect to their ability to participate in human subjects'
research.
Managing Investigator Burden
As these requirements became defined and we received
feedback from network members, it became clear to us
that the requirements were excessively burdensome. Sur-
veys of those members who completed all requirements
indicated that the time required by investigators to pro-
vide documentation that they had fulfilled these require-
ments was estimated to be ten to fifteen hours. Note that
this does not include any training for specific protocols.
Ultimately this proved to be a drag on investigator recruit-
ment and was complicated by the fact that CAPTN wasn't
budgeted to cover the time costs of these requirements.
For experienced researchers working in facilities with sup-
port infrastructure, such as a clinical research coordinator,
ten hours may not seem onerous, but for CAPTN mem-
bers, 80% of whom are in private practice, additional
paperwork of this magnitude was seen as an overwhelm-
ing barrier to participation. Consider that, in private prac-
tice, and particularly, in solo practices, every hour spent
on these activities means unseen patients and an opportu-
nity cost to the practice. Child and adolescent psychiatry
is a field where the wait to see a physician is six months in
many areas, meaning the time required to meet these
requirements occurred at a loss to patients, too. Recogniz-
ing that the burdens were more time-consuming than we
anticipated, we discussed the situation with our Steering
Committee, Scientific Advisory Board, and the programChild and Adolescent Psychiatry and Mental Health 2009, 3:12 http://www.capmh.com/content/3/1/12
Page 8 of 13
(page number not for citation purposes)
office at the NIMH, and made a decision to offer reim-
bursement for the costs of research above the costs of clin-
ical care. While we recognize that the costs of this time
differ based on overhead costs in different regions and
practice settings, we settled on reimbursement at $150 per
hour. This number was arrived at through both surveys
and a consideration of our ability to pay, based on re-
budgeting of the network coordinating center's funds
away from other activities.
As the burden of regulatory and other requirements
became clear to us, we recognized that innovative strate-
gies to lessen these burdens were imperative. We achieved
substantial cost savings by automating the collection of
regulatory information and moving this burden from
investigators to the study coordinating center. Ultimately,
the system we developed led to an enormous cost savings
and represents a significant advancement in recruitment
of clinical investigators. This system is described below.
In recent years, an increasing amount of information has
become available in electronic format. Although clinical
research and medicine in general has lagged other busi-
ness in terms of adoption of information technologies,
many organizations are actively moving towards elec-
tronic records. For CAPTN, we linked our web-based
enrollment survey system to a live database that inte-
grated physician licensure information from the Federa-
tion of State Medical Boards portal. Using custom scripts
for each state's web site we were able to quickly automate
collection of licensure information for about 85% of the
U.S. population. We combined this with imports of child
and adolescent psychiatry training, demographic, and
contract information from the AACAP database, board
certification information from an automated script for the
ABMS web site, DEA licensure information from the DEA
registrant database available from the National Technical
Information Service (NTIS), and FWA information from
the OHRP. This system enabled us to quickly document
investigator qualifications from reliable and valid infor-
mation sources.
When an investigator signs up for CAPTN through our
web site, we are able to match up the information pro-
vided on our short enrollment survey with this composite
database to verify that their credentials are current and
sufficient for membership in CAPTN. The information
from this survey is then merged into the NIH format BioS-
ketch and an email with a link to the required HSP train-
ing.
While this system, an aggregate of more than sixty live and
static databases, represents a significant innovation in
terms of documenting investigator qualifications under
21 CFR 312 and ICH 4.1.1, we feel that it may be a starting
point for easing the burdens of research across specialties.
Specifically, we envision a similar system operated cen-
trally by the NIH or FDA in a manner analogous to FWA
and IRB registries currently maintained by OHRP. A cen-
tral system, linking qualification databases such as medi-
cal licensure, residency training and board certification,
and DEA registrant information together with the HSP
training records database at the NCI and institutional
information from OHRP (IRB, FWA) could vastly simplify
the process of documenting investigator qualifications for
research, and provide a means for centrally tracking
research participation by oversight bodies within DHHS.
A convenient platform for such a project already exists, in
part, through the http://www.clinicaltrials.gov. The bene-
fits of joining these systems into a large clinical research
information architecture are that investigators would be
relieved of providing duplicate regulatory documents for
each trial that they participate in to sponsors who are
required to collect and process them. This reduced the
overall burden of research and facilitates the work of over-
sight agencies and IRBs by allowing real-time tracking of
qualifications and HSP training along with study partici-
pation.
Professionalism: Training Clinicians to be Clinical 
Researchers
A central myth in the field is the belief that being an expert
clinician entitles one to do treatment research. Nothing
could be further from the truth. While it is very helpful to
have good clinical skills, the research skills necessary to be
a Good Clinical Practice (GCP) compliant clinical trialist
or to effectively run a GCP compliant clinical trial site are
separate from the basic skills required for clinical practice.
Accordingly, CAPTN, which by intent recruited investiga-
tors without research experience, required us to put in
place a variety of vehicles for terrific clinicians to become
terrific research sites. In addition to the NCI's training or
training offered by a local IRB, we made research ethics
training created by Duke University's Trent Center for
Bioethics, Humanities, and the History of Medicine freely
available to all CAPTN investigators. These research ethics
training modules cover a wide variety of the ethical and
scientific aspects of performing human subjects' research.
The modules also provide free continuing medical educa-
tion (CME) credit. We felt that this was one potential ben-
efit of participating to physicians participating in CAPTN.
In addition to HSP training, we partnered with the Com-
munications Department at the Duke Clinical Research
Institute to offer a ten module series of on-line training in
clinical research through the CAPTN web site. This train-
ing is based on the clinical research textbook, Lessons
from a Horse Named Jim. This textbook was provided free
of charge to all CAPTN investigators after execution of theChild and Adolescent Psychiatry and Mental Health 2009, 3:12 http://www.capmh.com/content/3/1/12
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network MSA. Our aim was to provide both the book as a
reference and a tool for self-directed training in clinical
research. In the first two years that the on-line training
modules were available, fewer than a dozen network
members completed any of the training modules. This
may have been due, in part, to the fact that initially CEU,
but not CME was available for completing the modules.
In fact, the cost and requirements for obtaining accredita-
tion for these modules to provide CME was a barrier for
the coordinating center. We found that working through
the AACAP, which is an authorized provider of CME, sim-
plifies the offer of CME credit for training modules created
by CAPTN. Recently, we have completed modules on
Understanding in Incorporating Evidence-Based Medicine
into Clinical Practice and Understanding Issues of Diver-
sity in Clinical Research and Patient Recruitment. Addi-
tional modules are in development.
Cumulatively, CAPTN members were required to com-
plete about two hours of training prior to participating in
our first clinical research study. This training was delivered
via the web-based modules, teleconferences, and web
casts. Our experience in the first Network Initiation study
suggests that this training alone is not sufficient for new
clinical researchers.
Study Monitoring
One of the main costs, and thus barriers to, expanded clin-
ical research within the context of medical practice is the
cost of monitoring compliance at clinical sites. ICH 5.18.3
requires monitoring of clinical trial sites, but doesn't
define a minimal level of monitoring of research studies.
Since IRBs are required to review studies at least annually,
this has become the minimum standard for monitoring of
clinical research sites. Historically, clinical research moni-
tors (CRAs) have traveled to sites to verify source docu-
ments, conduct training or retraining, and assess
compliance with ethical and regulatory guidelines. For
our first Network Initiation study, we required internet-
based research ethics training and conducted a series of
web cast protocol training sessions that lasted about one
hour each. Coordinating Center personnel contacted sites
several times per month using phone, email, and/or fax to
answer questions, collect enrollment information, and
discuss the conduct of the study. Over the next year, we
physically monitored all sixty-five sites that participated
focusing on ethical and regulatory compliance. The find-
ings of these activities showed a large number of issues
with the performance and documentation of informed
consent at approximately half of PAERS sites.
Since most investigators were research naïve prior to this
study, we discovered post hoc that an hour each of ethics
and protocol training was insufficient for most clinicians
with respect to the execution of the informed consent
process. After working with sites to report these findings
to their IRB, we determined that the available training did
a good job of educating clinicians about the regulatory
and ethical aspects of doing human subjects research, but
did not give them a framework for implementing proce-
dures to comply with these guidelines. In response, we
created SOPs to help sites enact procedures that would
allow them to meet the requirements. In addition, we
have embarked on creating a professionally-produced,
web-based interactive training that is scenario-based and
makes extensive use of video. This educational module is
currently in production and will be completed and placed
in the public section of the CAPTN website in Quarter 1 of
2010.
Following this study, we surveyed participating investiga-
tors and discussed the findings with our Steering Commit-
tee. The at-large members were particularly helpful
explaining to the Steering Committee the specific burdens
created for doctors when they had to add additional time
to their patient care encounters (for example, for conduct-
ing informed consent discussions) or increase their over-
all paperwork burden. Indeed, three factors here are
particularly relevant for those attempting to increase par-
ticipation in medical research by physicians. First, pres-
sure from payers has reduced the amount of time child
and adolescent psychiatrists (and other specialists) are
able to spend with patients. Aggravating this is the severe
shortage of child and adolescent psychiatrists in North
America. Our surveys of participants and potential partic-
ipants indicated that their initial encounters with treat-
ment-seeking children and families lasted a median of
one hour. For medication management visits, the median
time spent with a patient was twenty-five minutes. CAPTN
reimburses for the cost of research above the cost of rou-
tine clinical care. After conducting our first study, we
found that it took an average of 45 minutes time to con-
duct the informed consent process with the family,
approximately thirty minutes to complete the research
portion of the clinical interview, and twenty-to-thirty
minutes to complete the case report forms required for
our study. While this is a tiny time allocation relative to
efficacy/effectiveness trials like the Treatment for Adoles-
cents with Depression (TADS) study[11,12], it is not
inconsequential for busy physicians. Hence, for participa-
tion in research to be financially neutral for physicians,
studies must be budgeted accordingly, and the budget for
site-based payments must be large enough to absorb the
sample sizes required in practical clinical trials.
The Data Safety and Monitoring Board
In addition to field monitoring for regulatory and ethical
compliance, a Data and Safety Monitoring Board (DSMB)
was established as an independent body to periodicallyChild and Adolescent Psychiatry and Mental Health 2009, 3:12 http://www.capmh.com/content/3/1/12
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evaluate the progress of CAPTN studies. This includes a
review of safety data for signals that might warrant modi-
fication, suspension, or discontinuation of a particular
study. In developing a charter for the Board, we made
extensive use of the NIH Policy on Data and Safety Moni-
toring, FDA's draft guidance on the establishment and
operations of Clinical Trial Data Monitoring Committees,
and the DAMOCLES study group's guidelines. In addi-
tion, members of our executive committee drew on their
own experiences chairing or serving on numerous
DSMBs/DMCs for NIH and industry.
When recruiting members of this board, the issue of liabil-
ity insurance reemerged. Although lawsuits against DSMB
members are rare, and have not, to our knowledge, been
successful, this remains a possibility and a barrier to
recruiting qualified candidates. This is specifically since it
is recommended that a majority of members be independ-
ent of the sponsoring institution (Duke, in our case).
Those serving on the board with appointments at Duke
would generally be covered under Duke's insurance but
Duke generally does not indemnify independent contrac-
tors, such as DSMB members, meaning that the external
members should either come from an institution that
would cover them or they must purchase their own cover-
age. As the importance of DSMBs increases, we anticipate
more difficulty in recruiting qualified candidates. To alle-
viate this, liability insurance or indemnification should be
made available to those agreeing to serve on these boards.
We required that members of our DSMB submit annual
Conflict of Interest and Financial Disclosure certifications
modeled after the policy for such disclosures at Duke. The
requirements for this disclosure stem from 21 CFR 54
and, for NIH-funded projects, such as CAPTN, 42 CFR 50.
The purpose of these disclosures is to ensure that those
participating in CAPTN research are fully objective.
Based on Duke's policy and the guidance available from
the NIH, FDA, and International Council of Medical Jour-
nal Editors, we crafted a financial disclosure and conflict
of interest (COI) policy for the network that is currently
applicable to CAPTN publications and CAPTN faculty.
Respecting the balance between the ethical and regulatory
need for full disclosure of competing interests and the
additional burden full disclosure might place on CAPTN
investigators participating in CAPTN research projects, we
are currently considering extending conflict of interest
reporting to all CAPTN investigators using the CAPTN
practice profiling tool, the Practice Research Survey.
Study Architecture
To realize the efficiencies of a research network, we sought
to develop a standard platform on which to capture clini-
cal trial information. This core Case Report Form battery
consisted of basic patient, practice, and diagnostic infor-
mation for screening and enrollment, along with a stand-
ard treatment-level form that included validated and
reliable measures of safety, tolerability, and efficacy.
Diagnostic and Outcomes Assessment
After extensive research, we chose the youth- and parent-
reported DISC Predictive Scale, version four (DPS-4) as
our diagnostic instrument. The DPS-4 contains a series of
questions drawn from the Diagnostic Interview Scale for
Children that can be answered with a simple yes or no.
The information provided can quickly be scanned by a cli-
nician to validate their clinical interview findings. Overall,
the use of scales should be part of the best practice stand-
ard-of-care, but such scales should not add extensive time
to the patient care encounter, or they would become unre-
alistic in clinical practice. To improve usability and to pro-
vide comparability to European PCTs, we considering a
switch from the DPS to the Health of the Nation Outcome
Scale for Children and Adolescents (HoNOSCA), which
comes in child, parent and clinician formats, is shorter
and simpler to administer and score than the DPS, and is
a proven clinical trial endpoint [13-17]
For evaluation of effectiveness of interventions, we chose
the Clinical Global Impressions, Severity and Improve-
ment scores (CGI-I, CGI-S) and the Child Global Assess-
ment Scale (CGAS). We ask clinicians to rate the severity
of primary illness, that for which study treatment was ini-
tiated, overall mental illness, and global functioning.
Where appropriate, we also ask the investigator to provide
Clinical Global Impressions-Tolerability (adverse event
burden) and Acceptability (formulation acceptability)
scores, which when combined with a CGI-I score allow
the investigator to provide a composite CGI-Effectiveness
score based on the balance of benefits, tolerability and
acceptability. Together, these simple measures provide a
reliable snapshot of the subject's diagnostic status and
functioning over time.
Adverse Event Monitoring
Adverse events (AEs) following treatment with psycho-
tropic medication are a common but understudied cause
of iatrogenic morbidity. Drug-induced, adverse events
(AEs), including suicidal events, are more common in
adolescents than in adults, and more common in children
than in adolescents. However, despite the availability of
valid and reliable PCT friendly diagnostic and endpoint
assessments, we found no suitable measure available for
adverse event elicitation. This is consistent with recent
critical reviews conducted by the Research Units on Pedi-
atric Psychopharmacology (RUPP) indicate that little is
known about the incidence and prevalence of AEs, espe-
cially less common events and, until recently, the field has
not had a standardized procedure for prospectively ascer-Child and Adolescent Psychiatry and Mental Health 2009, 3:12 http://www.capmh.com/content/3/1/12
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taining common, rare or unique treatment-specific AEs
[18-20].
Consistent with GCP standards and the goals of CAPTN
itself, safety monitoring is a primary aim of most if not all
CAPTN trials. To accomplish safety monitoring with the
framework of the CAPTN eCRF, we required (1) an AE
monitoring tool to identify and record common AEs and
(2) a mechanism for recording severe harms that would
be informative from a data perspective and would satisfy
DSMB/FDA requirements for serious adverse event report-
ing. To this end, using CAPTN as the platform, we devel-
oped and psychometrically validated a new AE rating
scale, the Pediatric Adverse Events Scale (PAERS), which is
designed to allow rigorous prospective identification of
AEs in a PCT framework [21,22]. Fully integrated with the
CAPTN eCRF, the PAERS addresses the following issues:
(1) simplicity and ease of use; (2) clinical applicability to
a wide variety of drug exposures; (3) frequency, severity,
and subjective importance of an AE; and (4) empirically-
derived, psychometrically validated item content. The
PAERS, which can be administered at every visit or at
selected visits, is a 45 item AE inventory estimated to take
10–15 minutes to complete. Forty-three items contain
empirically-derived and validated item content and 2
items are open. The PAERS includes child and parent
forms intended to set the prior probabilities for the clini-
cian to formally ascertain AEs the baseline and all post
baseline visits. Absent, a child or parent form, the PAERS
includes a clinician interview option. All three versions
use a Likert-style response format in which the informant
indicates how much each item (sign or symptom) was
bothersome or a problem. Having reviewed the items
with the patient and parent, the clinician records all AEs
and summary information on the PAERS clinician form
including specifying presence in the past week, resolution,
attribution, severity, and impact on function. Both for-
mats – child/parent and clinician interview – are accepta-
ble to doctors and patients and, hence, are frequently used
by CAPTN investigators in clinical practice.
While the PAERS provides an acceptable level of detail for
typical adverse events, it does not adequately assess seri-
ous or harm-related events. Thus, having reviewed the
PAERS, the study investigator also completes a separate
screen for parasuicidal behavior, suicidal ideation and
behavior, harm to others, and medical and psychiatric
serious adverse events. The eCRF also includes a section
on behavioral toxicity, including but not limited to behav-
ioral activation, agitation, akathisia, disinhibition, inhab-
itation, emergence or worsening of ADHD, and the
serotonin syndrome. Any or all of these or any severe
adverse event may then trigger the CAPTN eCRF SAE/
Harm Form. If the event is serious non-psychiatric (e.g.
hospitalization for a femur fracture), psychiatric (e.g.
mania or severe panic), or harm-related (suicidal event or
harm to others) so some combination of these, the clini-
cian will record systematic information in checklist form,
including: narrative description, seriousness assessment
(FDA SAE checklist), relationship to study medication,
event status, event characteristics, relationship between
multiple events, harm to self/others type and detailed
characterization, contributing factors, and event resolu-
tion. To avoid the necessity of event adjudication, the
CAPTN eCRF specifically provides for event coding under
the FDA's rubric for seriousness and the Columbia Suicide
coding scale[23,24]. Events are held open and tracked
until resolved. Branching logic allows for relatedness
across compound SAEs. At the next visit, an event resolu-
tion workflow is automatically triggered until the event is
resolved or the patient exits the study.
The CAPTN eCRF
After gathering feedback about the CRF and assessment
measures, and extensive analysis of the study data, we
revised and finalized our core CRF battery. This battery
was then built into an electronic format using Clinipace's
TEMPO electronic data capture (EDC) system. This system
allowed us to make extensive use of logic checks and
branching to minimize the number of questions an inves-
tigator would need to answer about a study patient, based
upon their answers to pervious questions. The validation
allowed us to enact complex logic checks on screen, elim-
inating the need for post hoc queries which are not feasible
in a PCT setting. This system is currently being used in the
CAPTN Antidepressant Safety in Kids (ASK) trial as well as
in a pharmacogenomic sub-study looking at genetic pre-
dictors of suicidality and behavioral activation, among
other endpoints, and will be portable with minor modifi-
cations for all future CAPTN practical clinical trials. A
standard platform, shared across the network allows a sig-
nificant cost savings across studies.
Conclusion
It is widely acknowledged that clinical trials in psychiatry
frequently fail to maximize clinical utility for practicing
clinicians, or stated differently, available evidence isn't
perceived by clinicians (and other decision makers) as suf-
ficiently relevant to clinical practice, thereby diluting its
impact [4]. To maximize clinical relevance and acceptabil-
ity, researchers in other areas of medicine – such as cancer
and cardiology – have turned to practical clinical trials,
which are always simpler and usually larger than conven-
tional efficacy clinical trials [8]. We recently made the case
for transporting the practical clinical trials model to psy-
chiatry, defining requirements for stable funding for net-
work construction and maintenance plus methodological
innovation in assessment, treatment, data management,
site management, and data analytic procedures. [5].Child and Adolescent Psychiatry and Mental Health 2009, 3:12 http://www.capmh.com/content/3/1/12
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During its first five years, CAPTN successfully addressed
the aims of the NIH roadmap. Specifically, we have made
extensive use of information technologies to developed
innovative solutions to reduce the burden and cost of clin-
ical research. In addition, were have responded to the
charge of setting the research agenda with input from a
wider array of stakeholders by partnering with the AACAP
and enlisting representatives from advocacy organiza-
tions. Together, these have allowed us to move the field
forward and prove the feasibility of PCTs as part of an
overall move towards increasing the use of EBM in the
field of child and adolescent psychiatry. Over the next two
years, CAPTN will complete the largest safety registry ever
in its field – a 500+ subject patient safety study of antide-
pressants that will include specific measures for safety
monitoring and evaluation of behavioral activation and
its putative link to treatment-emergent suicidality. This
will be coupled with a pharmacogenomic study to assess
genetic markers for antidepressant benefits and harms. In
addition, CAPTN is in the process of conducting an equi-
poise stratified randomized comparison of newer versus
older medications in ADHD. The information gained will
meaningfully improve the ability of both clinical and pol-
icy decision-makers to make decisions in the best interests
of youth with mental illness.
In response to PAR-08-088 for Advanced Centers for Inter-
ventions and/or Services Research (ACISR), the CAPTN
team is in the process of applying for a second five years
of NIMH funding. If successful, CAPTN will complete
ongoing studies; expand to 250 active participants includ-
ing an extension into Developmental and Behavioral
Pediatrics; restandardize and disseminate the PAERS; ini-
tiate a pioneering programs of research in diversity, office-
based parent management training in ADHD, and adap-
tive treatment strategies in pediatric bipolar disorder; add
collaborative NIMH- and industry-funded clinical trials
and in so doing open the Network to outside researchers
wishing to use CAPTN to conduct PCTs; conduct jointly
with the NIMH five field-leading workshops on topics rel-
evant to practical clinical trials in pediatric psychiatry; and
expand career development initiatives begun during the
first five years of funding. Accordingly, CAPTN promises
to enhance the public health relevant evidence base in
pediatric psychopharmacology and to further develop the
capacity to conduct practical clinical trials in mentally ill
children and adolescents.
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